ReNerve Limited is a medical device company developing tissue-based products for peripheral nerve repair and replacement and, other related soft tissue surgical procedures. The company is focused on improving outcomes for patients by creating the ideal healing environment for soft tissue repairs and the related regeneration.
ReNerve has established laboratories in Melbourne, Australia and also works closely with researchers in one of Australia’s premier biomaterials precincts at the CSIRO/Monash University.
The company is focused on developing products that accelerate tissue regeneration while preventing scarring and negative inflammatory responses. The company’s lead programs are focused on peripheral nerve repair; however, have the potential for application beyond peripheral nerve repair.
It is anticipated that RNV will list list on the ASX during November 2024.
